Kura Oncology (NASDAQ:KURA) Shares Gap Down – Time to Sell?

Kura Oncology, Inc. (NASDAQ:KURA) shares gapped down prior to trading on Thursday . The stock had previously closed at $9.05, but opened at $8.15. Kura Oncology shares last traded at $7.77, with a volume of 1,473,412 shares trading hands.

Wall Street Analyst Weigh In

KURA has been the subject of a number of research analyst reports. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $26.00 to $19.00 in a report on Monday, October 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. UBS Group began coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target on the stock. Jefferies Financial Group dropped their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Finally, BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Stock Down 1.9 %

The business’s 50 day moving average price is $8.79 and its two-hundred day moving average price is $15.11. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter last year, the firm posted ($0.50) earnings per share. Equities analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Insider Activity

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This represents a 5.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,255 shares of company stock worth $100,739 over the last quarter. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Moody Aldrich Partners LLC boosted its holdings in shares of Kura Oncology by 42.3% during the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after buying an additional 42,712 shares during the period. SG Americas Securities LLC acquired a new position in Kura Oncology during the 4th quarter worth $436,000. Harbor Capital Advisors Inc. boosted its holdings in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after acquiring an additional 2,076 shares during the period. JPMorgan Chase & Co. grew its position in shares of Kura Oncology by 0.8% in the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after purchasing an additional 3,092 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after purchasing an additional 1,976 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.